1. Agid Y, Javoy F, Glowinski J (1973) Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigrostriatal dopaminergic system in the rat. Nature 245: 150–151
2. Agid Y, Bonnet AM, Signoret JL, Lhermitte F (1979) Clinical, pharmacological and biochemical approach of “onset and end-of-dose” dyskinesias. In: Poirier LJ, Sourkes TL, Bedard PJ (eds) Advances in neurology, vol 24. Raven, New York, pp 401 –409
3. Barbeau A (1976) Neurological and psychiatric side-effects of L-DOPA. Pharmacol Ther 1: 475–494
4. Barbeau A, Mars H, Gillio-Joffroy L (1971) Adverse clinical side-effects of levodopa therapy. In: McDowell FH, Markham CH (eds) Parkinson’s disease. Davis, Philadelphia, pp 203–237
5. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415–455